
Kluwer Patent Blog

Patent case: Pharmathen Global B.V. vs. Novartis AG, Netherlands

Bart van Wezenbeek (Hoffmann Eitle) · Monday, October 28th, 2024

After Novartis had obtained a preliminary injunction against Pharmathen, it observed that there were still infringing acts being performed. In the first instance, the provisions judge sided with Novartis and ordered that Pharmathen had to pay EUR 7,500,000 as a penalty. On appeal Pharmathen tried to reverse this verdict, but its efforts were in vain.

Case date: 26 March 2024

Casa number: 200.321.764/01

Court: Court of Appeal of Amsterdam

A full summary of this case has been published on [Kluwer IP Law](#)

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change

This entry was posted on Monday, October 28th, 2024 at 1:27 pm and is filed under [Case Law](#), [Infringement](#), [Netherlands](#), [Pharma](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. You can leave a response, or [trackback](#) from your own site.